Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies
Go back to Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies| (NYSE: TAK) | Delayed: 18.91 -0.14 (0.73%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $19.05 | 52 Week High | $0.55 | |||
| Open | $18.80 | 52 Week Low | $0.55 | |||
| Day High | $19.01 | P/E | N/A | |||
| Day Low | $18.80 | EPS | $-0.20 | |||
| Volume | 2,960,710 | |||||
